Applications

1750 – Testing of tumour tissue to detect IDH1 mutations in patients with cholangiocarcinoma to determine eligibility for ivosidenib on the Pharmaceutical Benefits Scheme

Find out about the service or technology in this application and the medical condition it addresses. You can also view the application documents, the deadlines for providing consultation input and the outcome of the application when the MSAC process is complete.

  • Status Complete
  • Type New application
  • Pre-PASC consultation Closed
  • Pre-MSAC consultation Closed
  • Outcome Deferred

Application details

Reason for application

New MBS item.

Service or technology in this application

Testing of tumour tissue by a pathologist, for patients with locally advanced or metastatic Cholangiocarcinoma, to detect IDH1 mutations. Confirmation of the disease will be required to determine eligibility for treatment with Tibsovo® (ivosidenib), which is seeking PBS listing through a codependent submission.

Type: Investigative technology

Medical condition this application addresses

Cholangiocarcinoma is a type of cancer that encompasses all tumours originating from the epithelium of the bile duct. Bile ducts are a group of thin tubes that carry bile (a digestive fluid) from the liver and gallbladder into the intestines.

Application documents

Application summary

PICO set

Consultation survey

PICO confirmation

Public summary document

We aim to provide documents in an accessible format. If you're having problems using a document with your accessibility tools, please contact us for help.

Consultation survey and deadlines

  • PASC consultation: Closed
  • MSAC consultation: Closed Friday 14 June 2024

Meetings to consider this application

  • PASC meeting: 10–11 August 2023
  • ESC meeting: 13–14 June 2024
  • MSAC meeting: 
    • 1– 2 August 2024
    • 28–29 November 2024